Abstract
Background: The development and risk potential of hypertension-induced left ventricular (LV) hypertrophy has been well described in epidemiological studies. Regression of LV hypertrophy reduces cardiovascular morbidity and mortality. However, the best treatment strategy is still debated, as well as the appropriate blood pressure target in these patients.
Objective: We here review the treatment of LV hypertrophy and the potential benefit on clinical outcomes, against a background of the epidemiology and pathophysiology.
Results: Both hemodynamic and non-hemodynamic mechanisms contribute to hypertensive LV hypertrophy, which is characterized by an inappropriate myocardial fibrosis. Stringent blood pressure control reduces LV hypertrophy. Blockers of the renin-angiotensin-aldosterone system may have valuable effects on cardiac and electrophysiological remodelling beyond the effects of blood pressure reduction. Thus, they represent a cornerstone in the treatment of hypertensive LV hypertrophy, but most often other antihypertensive drug classes need to be added. Current guidelines indicate a blood pressure target in most patients with hypertensive LV hypertrophy of 120–130/80 mmHg.
Conclusions: LV hypertrophy and myocardial fibrosis are important characteristics of hypertensive heart disease and associated with untoward prognosis. Regression of LV hypertrophy reduces cardiovascular morbidity and mortality. New drugs under development may add additional benefit.
Keywords: Cardiac hypertrophy, fibrosis, hypertensive heart disease, hypertension, renin-angiotensin-aldosterone system, treatment.
Current Pharmaceutical Design
Title:Treatment of Hypertensive Left Ventricular Hypertrophy
Volume: 24 Issue: 37
Author(s): Andreas Jekell, Peter M. Nilsson*Thomas Kahan
Affiliation:
- Lund University, Department of Clinical Sciences, Skane University Hospital, Malmo,Sweden
Keywords: Cardiac hypertrophy, fibrosis, hypertensive heart disease, hypertension, renin-angiotensin-aldosterone system, treatment.
Abstract: Background: The development and risk potential of hypertension-induced left ventricular (LV) hypertrophy has been well described in epidemiological studies. Regression of LV hypertrophy reduces cardiovascular morbidity and mortality. However, the best treatment strategy is still debated, as well as the appropriate blood pressure target in these patients.
Objective: We here review the treatment of LV hypertrophy and the potential benefit on clinical outcomes, against a background of the epidemiology and pathophysiology.
Results: Both hemodynamic and non-hemodynamic mechanisms contribute to hypertensive LV hypertrophy, which is characterized by an inappropriate myocardial fibrosis. Stringent blood pressure control reduces LV hypertrophy. Blockers of the renin-angiotensin-aldosterone system may have valuable effects on cardiac and electrophysiological remodelling beyond the effects of blood pressure reduction. Thus, they represent a cornerstone in the treatment of hypertensive LV hypertrophy, but most often other antihypertensive drug classes need to be added. Current guidelines indicate a blood pressure target in most patients with hypertensive LV hypertrophy of 120–130/80 mmHg.
Conclusions: LV hypertrophy and myocardial fibrosis are important characteristics of hypertensive heart disease and associated with untoward prognosis. Regression of LV hypertrophy reduces cardiovascular morbidity and mortality. New drugs under development may add additional benefit.
Export Options
About this article
Cite this article as:
Jekell Andreas , Nilsson M. Peter *, Kahan Thomas , Treatment of Hypertensive Left Ventricular Hypertrophy, Current Pharmaceutical Design 2018; 24 (37) . https://dx.doi.org/10.2174/1381612825666181203092918
DOI https://dx.doi.org/10.2174/1381612825666181203092918 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Flaxseed on Blood Lipid Level in Hyperlipidemic Patients
Reviews on Recent Clinical Trials Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review
Current Pharmaceutical Biotechnology Hormone Replacement Therapy in Rheumatoid Arthritis
Current Rheumatology Reviews Recent Development and Future Prospects of Plant-Based Vaccines
Current Drug Metabolism Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Flavonoids for Allergic Diseases: Present Evidence and Future Perspective
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Diabetic Cardiomyopathy and Oxidative Stress: Role of Antioxidants
Cardiovascular & Hematological Agents in Medicinal Chemistry Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Glucose-6-Phosphate Dehydrogenase Deficiency: Disadvantages and Possible Benefits
Cardiovascular & Hematological Disorders-Drug Targets Hematocrit-lowering Effect Following Inactivation of Renin-Angiotensin System with Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
Current Topics in Medicinal Chemistry A Novel Therapeutic Strategy Against Vascular Disorders with Chymase Inhibitor
Current Vascular Pharmacology Mechanisms of Inflammatory Atherosclerosis in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) Arterial Duct Stenting in Congenital Heart Disease with Duct-Dependent Pulmonary Circulation
Current Pediatric Reviews The Role of Endothelial Progenitor Cells and Statins in Endothelial Function: A Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Differential Developmental Origin of Arteries: Impact on Angiogenesis and Arteriogenesis
Medicinal Chemistry Reviews - Online (Discontinued) Stem Cells as a Novel Tool for Drug Screening and Treatment of Degenerative Diseases
Current Pharmaceutical Design Flow and Microwave Assisted Synthesis of Medicinally Relevant Indoles
Current Green Chemistry Prevalence and Related Factors of Sarcopenia in Community-dwelling Elderly with Long-term Care Insurance
Reviews on Recent Clinical Trials Cytokines as Regulators of Atherosclerosis in Murine Models
Current Drug Targets